Welcome | Curriculum | Clincal Rotations | Conference Schedule | Research Opportunities Clinical Faculty | Application Process | Contact | Recent Peer-Reviewed Publication

Welcome!

Thank you for your interest in the Fellowship Program in Infectious Diseases at Beth Israel Medical Center. The Division, under the leadership of Donna Mildvan, M.D., has 10 full-time faculty, 1 part-time faculty, and 4 fellows (2 per year). We provide tertiary care across the entire spectrum of infectious disease illnesses to the diverse patient population of the Lower East side of Manhattan. The Division offers an inpatient consultative service as well as training in outpatient infectious diseases.

top

Curriculum

The fellowship is a two year program of clinical training, with 7 months devoted to the performance of a clinical research project. In addition to general infectious diseases inpatient consultations, there are rotations in transplant infectious diseases, infection control, sexually transmitted infections, pediatric infectious diseases, and the microbiology laboratory. Fellows follow a panel of patients in their weekly ambulatory sessions in the Peter Krueger HIV Clinic, and see other patients in monthly general infectious disease clinic sessions.

Goals, Objectives and Educational Purpose:

Over the two year training programs, fellows will:

• Gain an understanding of the epidemiology and pathogenesis of infectious diseases and of host interactions with microbial pathogens.
• Acquire a detailed fund of knowledge regarding the prevention, diagnosis, and treatment of the major infectious disease syndromes.
• Develop the clinical skills necessary to identify and evaluate patients with infectious disease problems.
• Become proficient in the management of infectious diseases encountered in the inpatient and outpatient settings.
• Acquire a detailed fund of knowledge of the various classes of antimicrobial drugs, biological response modifiers, and vaccines and their appropriate use.
• Become thoroughly familiar with procedures used in the clinical microbiology laboratory and make efficient, effective, and critical use of laboratory data in the diagnosis and management of infectious diseases.
• Develop skills necessary to design, conduct, and evaluate research in the area of infectious diseases.
• Assimilate principles and practice skills required by the hospital-based specialist, including hospital epidemiology, infection control, and quality improvement.
• Adopt a critical approach to the infectious disease literature.
• Develop the interpersonal skills, professional attitudes, and humanistic qualities required of an infectious disease specialist.

top

Clincal Rotations

top

Conference Schedule

Fellows are expected to attend all conferences, which include the ID Grand Rounds, Journal Club, and Research Conference. Fellows will also participate in the "Summer Lecture Series Didactics", a comprehensive series of talks given by ID attendings.

top

Research Opportunities

Research is an important component of our training program and fellows are required to spend dedicated research time pursuing investigative work. Opportunities exist in all aspects of infectious diseases. A list of the most recent peer-reviewed publications from our Division is shown at the bottom of this website page so you can see the breadth and scope of our research interests.

top

Clincial Faculty

Application Process

The Infectious Diseases Fellowship Program participates in ERAS-Electronic Residency Application Service and NRMP-National Resident Match Program.

Contact

For any additional information regarding the Infectious Diseases Fellowship Program, contact:

top

Recent Peer-Reviewed Publication from the Division

1. Mildvan D, Creagh T, and Leitz G for the Anemia Prevalence Study Group. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human immunodeficiency virus-infected patients: findings on the anemia prevalence study. Curr Med Res Opin. 2007;23(2):343-355.
2. King WD, DeFreitas D, Smith K, Andersen J, Perry-Patton L, Adeyemi T, Mitty J, Fritsche J, Littles M, Fischl M, Pavlov G, and Mildvan D. Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: a descriptive study. AIDS Patient Care and STDs. 2007;21(8):551-63.
3. Riddler SA, Haubrich R, DiRenzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lailoo UAG, Murphy RL, Swindells S, Havlir D, Mellors JW, AIDS Clinical Trials Groups Study A5142 Team (including Mildvan D). Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-106.
4. Collier AC, Tierney C, Downey GF, Eshleman SH, Kashuba A, Klingman K, Vergis EN, Pakes GE, Rooney JF, Rinehart A, Mellors JW, AIDS Clinical Trials Group Protocol A5143 Team (including Mildvan D). Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease-inhibitor experienced patients with HIV. HIV Clin Trials. 2008;9(2):91-102.
5. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, KulkP, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E, Merck V520-016 Study Group (including Mildvan D). Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008;46(11):1769-81.
6. Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dube M, Grinspoon S, Robbins GK, Motsinger AA, Kalianpur AR, AIDS Clinical Trials Group 384 and A5005s Study Teams (including Mildvan D). Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis. 2008;197(6):858-66. Erratum in: J Infect Dis. 2008 Jun 1;197(11):1630.
7. Aaron S, McMahon J, Milano D, Torres L, Clatts M, Tortu S, Mildvan D, and Simm M. Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clin Infect Dis. 2008;47(7):931-4.
8. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, MOTIVATE Study Teams (including Mildvan D). Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14);1429-41.
9. Fatkenhauer G, Nelson M, Lazzarin A, Konourina I, Hoepalman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 AND MOTIVATE 2 Study Teams (including Mildvan D). Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359(14):1442-55.
10. De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J, Di Gambenedetto S, Cingolani A, Taoufik Y, Miralles P, Marra CM, Antinori A, Gesida 9/99; IRINA, ACTG 363 Study Groups (including Mildvan D). Cidofovir in addition to antiretroviral treatment in not effective for AIDS-associated progressive multifocal leukoencephalopathy; a multicohort analysis. AIDS. 2008;22(14):1759-67.
11. Koll BS, Straub TA, Jalon HS, Block R, Heller KS, Ruiz RE. The CLABs collaborative: a regionwide effort to improve the quality of care in hospitals. Jt Comm J Qual Patient Saf. 2008 Dec;34(12):713-23.
12. Kritchevsky SB, Braun BI, Bush AJ, Bozikis MR, Kusek L, Burke JP, Wong ES, Jernigan J, Davis CC, Simmons B; TRAPE Study Group (including Koll B) The effect of a quality improvement collaborative to improve antimicrobial prophylaxis in surgical patients: a randomized trial. Ann Intern Med. 2008 Oct 7;149(7):472-80, W89-93.
13. Masson CL, Sorenson JL, Perlman DC, Shopshire MS, Delucchi KL, Chen T, Sporer K, Des Jarlais D, Hall SM. Hospital- versus community-based syringe exchange: a randomized controlled trial. AIDS Educ Prev. 2007 Apr;19(2):97-110.
14. Des Jarlais DC, Hagan H, Arasteh K, McKnight C, Perlman D. Herpes simplex virus-2 and HIV among noninjecting drug users in New York City. Sex Transm Dis. 2007;34(11):923-7.
15. D’Amico R, Sarkar S, Yusuff J, Azar E, Perlman DC. Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy. Scand J Infect Dis. 2007;39(4):347-50.
16. Perlman D, Leung CC, Yew WW. Treatment of tuberculosis in HIV-infected patients: we need to know more. Am J Respir Crit Care Med. 2007 Jun 1;175(11):1102-3.
17. Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Friedman SR. Using hepatitis C virus and Herpes simplex virus-2 to track HIV among injecting drug users in New York City. Drug and Alcohol Dependence, 2008.
18. Deutscher M, Perlman DC. Why some injection drug users lick their needles: a preliminary survey. Int J Drug Policy. 2008;19(4):342-5.
19. Wohl DA, Pilcher CD, Evans S, Revuelta M, McComsey G, Yang Y, Zackin R, Alston B, Welch S, Basar M, Kashuba A, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H, Koletar SL; Adult AIDS Clinical Trials Group A5129 Team. Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):274-8.
20. Revuelta M. Cumulative insults to mitochondrial function may promote the emergence of 'syndrome X' and diabetes mellitus in HIV/HCV co-infected patients. Mitochondrion. 2004 Jul;4(2-3):175-84.
21. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006 Sep 1;43(5):645-53.
22. Karam C, Revuelta M, and Macgowan D. Human herpesvirus 6 meningoradiculitis treated with intravenous immunoglobulin and valganciclovir. J Neurovirol 2008 Sep 26 :1.
23. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis. 2005 May 15;40(10):1429-34.
24. Ruhe JJ, Menon A. Clinical significance of isolated Staphylococcus aureus central venous catheter tip cultures. Clin Microbiol Infect. 2006 Sep;12(9):933-6.
25. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007 Mar 15;44(6):777-84
26. Ruhe JJ, Menon A. Tetracyclines as an Oral Treatment Option for Patients with Community Onset Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007 Sep;51(9):3298-303
27. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, Schweitzer P, Yancovitz SR, Lapin JA, Shaiova L, Sheu RG, Portenoy RK. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage. 2005 Apr;29(4):385-91.
28. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Beatrice S, Milliken J, Mildvan D, Yancovitz S, Friedman SR. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005 Aug;95(8):1439-44.
29. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, Yancovitz S, Friedman SR. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS. 2005 Oct;19 Suppl 3:S20-5.

top